Since 2011, MultiPark’s innovation grants have supported researchers in transforming academic discoveries into solutions that benefit patients and society. With a total of 3.8 MSEK distributed across 21 early-stage projects, the initiative has delivered tangible results in the innovation landscape.
So far, the program has led to six patent filings, two proprietary algorithms, and the commercialization of four discoveries. Importantly, it has also contributed to the formation of companies, generating employments and tax revenue beyond academia.
Moreover, four grants have contributed to commercializing discoveries in the following areas: Alzheimer’s Disease Therapeutics, as well as Pharmacological, Gene, and Cell Therapies intended for treatment of Parkinson’s disease, stroke and Huntington’s disease.
The outcome of our innovation grants is good,” concludes Tadeusz Wieloch.
“Considering that commercialization of discoveries from basic ideas may take up to 15–20 years, and that the success rate of a preclinical discovery reaching a clinical development is at best 5 in 10 000, the outcome of our innovation grants is good,” concludes Tadeusz Wieloch, member of the MultiPark Innovation Board, in the outcome report.
Several projects have also sparked collaborations with pharmaceutical companies and produced publications in high-impact journals. In addition, MultiPark’s innovation grants have helped researchers secure follow-up funding from national agencies like VINNOVA and private investors, acting as a crucial catalyst for real-world progress.
